Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)‘s stock had its “buy” rating reiterated by equities research analysts at BMO Capital Markets in a research note issued to investors on Wednesday. They presently have a $196.00 price target on the specialty pharmaceutical company’s stock. BMO Capital Markets’ price objective would indicate a potential upside of 32.63% from the stock’s previous close.
Several other research analysts also recently weighed in on the stock. Deutsche Bank AG reissued a “buy” rating and issued a $176.00 target price on shares of Jazz Pharmaceuticals PLC in a research note on Tuesday, July 4th. Vetr raised shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $151.11 target price for the company in a research note on Tuesday, June 6th. Piper Jaffray Companies set a $182.00 target price on shares of Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research note on Friday, July 14th. Royal Bank Of Canada reissued a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, August 9th. Finally, Mizuho downgraded shares of Jazz Pharmaceuticals PLC from a “buy” rating to a “neutral” rating and cut their target price for the company from $162.00 to $150.00 in a research note on Tuesday, July 4th. One research analyst has rated the stock with a sell rating, three have given a hold rating and nineteen have issued a buy rating to the company. Jazz Pharmaceuticals PLC presently has a consensus rating of “Buy” and an average price target of $180.96.
Jazz Pharmaceuticals PLC (JAZZ) traded up 0.28% during midday trading on Wednesday, hitting $148.20. 8,948 shares of the stock were exchanged. The firm’s 50 day moving average price is $148.82 and its 200 day moving average price is $150.52. The company has a market cap of $8.90 billion, a PE ratio of 22.83 and a beta of 1.13. Jazz Pharmaceuticals PLC has a 12 month low of $95.80 and a 12 month high of $163.75.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.85 by ($0.13). The firm had revenue of $394.39 million for the quarter, compared to analyst estimates of $410.83 million. Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. The company’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same period last year, the firm earned $2.67 EPS. On average, equities research analysts forecast that Jazz Pharmaceuticals PLC will post $10.89 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “BMO Capital Markets Reiterates Buy Rating for Jazz Pharmaceuticals PLC (JAZZ)” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://sportsperspectives.com/2017/09/22/bmo-capital-markets-reiterates-buy-rating-for-jazz-pharmaceuticals-plc-jazz.html.
In other news, EVP Suzanne Sawochka Hooper sold 4,580 shares of the business’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $160.00, for a total transaction of $732,800.00. Following the completion of the sale, the executive vice president now owns 32,322 shares in the company, valued at approximately $5,171,520. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael Patrick Miller sold 200 shares of the business’s stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $154.97, for a total value of $30,994.00. The disclosure for this sale can be found here. Insiders have sold a total of 8,297 shares of company stock valued at $1,279,417 in the last quarter. Company insiders own 4.30% of the company’s stock.
Several large investors have recently modified their holdings of JAZZ. Toronto Dominion Bank grew its holdings in shares of Jazz Pharmaceuticals PLC by 12.4% during the 2nd quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock worth $114,000 after purchasing an additional 81 shares during the period. US Bancorp DE boosted its holdings in Jazz Pharmaceuticals PLC by 94.4% in the 2nd quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock worth $118,000 after acquiring an additional 368 shares during the period. Envestnet Asset Management Inc. boosted its holdings in Jazz Pharmaceuticals PLC by 43.0% in the 1st quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock worth $141,000 after acquiring an additional 295 shares during the period. World Asset Management Inc purchased a new position in Jazz Pharmaceuticals PLC in the 1st quarter worth approximately $205,000. Finally, Gargoyle Investment Advisor L.L.C. purchased a new position in Jazz Pharmaceuticals PLC in the 2nd quarter worth approximately $206,000. Institutional investors and hedge funds own 88.24% of the company’s stock.
Jazz Pharmaceuticals PLC Company Profile
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.